PPARG and metabolic dysfunction-associated steatotic liver disease: Finally, PPARG protects against MASLD, PPARG deficiency causes familial partial lipodystrophy 3 that presents with steatosis [55], and PPAR-γ agonists like pioglitazone are under clinical investigation for MASLD [56].